What if we stopped treating aging as “natural” and started treating it like a disease?
In this episode of the Molecule Podcast, Ella McCarthy-Page (Sci Comms Lead at Molecule)and Alana Tara Singh (Behavioural Strategist) unpack a seismic shift in how governments are approaching longevity science. The German National Academy of Sciences has officially defined aging as a disease target, opening the door for clinical trials, new drug development, and the first regulatory frameworks focused on reversing age-related decline.
They’re joined by Michael Torres (co-founder, R10 Bio & VITA RNA), who shares why he’s launching a human clinical trial targeting post-chemo aging in Abu Dhabi, a country now fast-tracking longevity drugs under radical new trial standards.
You’ll learn:
* Why aging wasn’t treatable (until now)
* What Germany’s new policy really means
* How Rapamycin exposed the flaws in current regulation
* Why Abu Dhabi is leading the longevity race
* The role of DeSci in decentralized drug development
* How R10 Bio used Molecule’s IP-NFT model to raise funds
* The real story behind Michael’s anti-aging therapy
Welcome to the future of proactive medicine! Let’s reimagine aging before it redefines us.
Timestamps:
00:00 – Intro with Ella & Alana
00:34 – Germany now targets aging as a disease
01:30 – Why regulators blocked anti-aging drugs
02:40 – Rapamycin and the loophole problem
04:00 – Why off-label drugs are risky
05:20 – Germany’s surprise leadership in longevity
06:00 – Abu Dhabi’s radical trial reforms
09:15 – Raves, cappuccinos & Gen Z health trends
10:00 – Can we prevent cancer by targeting aging?
10:50 – What is R10 Bio’s therapy actually doing?
12:00 – The DeSci fundraising journey with Molecule
13:10 – From mutation suppression to clinical readiness
14:00 – Why Abu Dhabi was chosen for trials
14:40 – Michael Torres on aging post-chemo
16:00 – Defining a huge market with aging-related outcomes
17:00 – Why rare disease trials don’t scale
18:00 – How Abu Dhabi is implementing FDA “guidance”
What if your healthspan was backed by a token? What if trading fees funded science? And what if longevity wasn’t just about “not dying”, but about living better for the ones you love?
In this episode of the Molecule Podcast, we dive deep with Jillian and Benji, the team behind Pump Science, a protocol that combines crypto markets with open scientific experimentation to find real longevity compounds. But this episode isn’t just technical. It’s deeply human.
From bonding curves and tokenomics to holding your child longer, this is what decentralized science looks like when purpose meets protocol.
We cover:
* The emotional “why” behind longevity research
* How crypto markets fund real scientific experiments
* Testing pipeline: from worms to flies to mice to humans
* The design of the Pump Science game, and how it rewards curiosity
* How you can submit your own idea for a longevity compound
* What’s next for Pump Science
This is more than a podcast, it’s a thesis on how the future of health could be fun, fair, and radically open.
—
Timestamps:
0:00 – Intro: Do you want to live for tomorrow?
1:45 – A mother’s promise: holding her son longer
5:35 – Longevity as emotional responsibility
8:12 – Why crypto is the only viable engine
10:10 – Pump Science protocol explained from first principles
14:42 – Launching a compound via bonding curve
17:55 – Who are the players? Drug devs & gem hunters
24:18 – What happens when a token “migrates”
29:34 – How token trading fees fund real experiments
32:20 – The buyback & burn mechanic
37:02 – The new standard for supplement + data
39:15 – Why not wait for human data? Worms, flies & predictive efficiency
48:04 – Pump Science vs other longevity efforts (Brian Johnson, etc.)
50:25 – How much has actually been studied in longevity?
55:00 – Why this system must exist, or nothing will change
57:02 – Making science fun again: designing a game people want to play
1:00:00 – Fly racing & the next experimental features
1:02:30 – Launching more tokens, testing more ideas
1:04:05 – How you can submit your own compound
1:05:40 – Final vision: best products, open data, real change
🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1
______
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to:
______
Let's connect:
Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.gg/ZHGpJQzeTq
Molecule - The future of medicine belongs to everyone
What if your immune cells came with a smart upgrade?In this episode of the DeSci Podcast, we speak with Dr. Henry Erdlei, medical doctor, cancer researcher, and founder of GoCart, a new cell therapy platform building safer, modular CAR-T therapies through decentralized science.Henry breaks down:* How CAR-T cell therapies work* The real-world risks of immune overactivation* Why cancer is hard to distinguish from healthy tissue* The problem with existing logic gates in cell therapies* His own innovation: an external AND-gate adapter system* Why DeSci and IP-NFTs are the right path for early-stage therapeutics🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1______If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.toTimestamps0:00 – Intro: What is CAR-T therapy?2:00 – Henry’s background & journey into cancer research4:20 – What T-cells do and why they fail in cancer7:30 – CAR-T vs chemotherapy: cost, complexity, and potential11:00 – Which cancers are eligible for CAR-T treatment?13:10 – Risks: cytokine storms, immune cascades, suicide switches17:30 – Emily Whitehead: the first CAR-T success story20:30 – Current limitations of approved CAR-Ts (CD19, BCMA)23:00 – Introducing GoCart and their “AND gate” design26:00 – Why tumor targeting needs precision logic29:00 – Modular CAR-Ts and the future of personalized medicine32:00 – Why GoCart is building in public with Molecule34:30 – Can DeSci unlock truly customizable cell therapies?37:00 – From research to startup: bridging the valley of death40:00 – How to follow GoCart and get involved______Let's connect: Website: https://bit.ly/3d6nh2CTwitter: https://twitter.com/Molecule_daoDiscord: https://discord.gg/ZHGpJQzeTqMolecule - The future of medicine belongs to everyone
What if you were told that your body is secretly responding to Wi-Fi signals you can't even feel?In episode 49 of the Molecule Podcast we meet Dr. Geoff Anders (Founder, Leverage) and Dr. Clarice D. Aiello (Quantum Engineer), to explore the cutting-edge field where quantum physics meets biology, revealing how the smallest particles in the universe might be controlling the largest processes in life itself. Whether you're a scientist, technologist, or simply curious about the quantum world around us, this deep dive into quantum biology will change how you think about life, technology, and the future of medicine. • Quantum biology explained in simple terms• Weak magnetic field effects on cellular processes• The radical pair mechanism and quantum sensing in nature• Space exploration and magnetic field implications• DeSci (Decentralized Science) and crypto funding for research• The future of quantum-controlled medicine• Open science and radical transparency in researchTake a leap into the never ending world of science and imagination with this podcast.Timestamps:00:00:02 - Introduction to Quantum Biology00:02:31 - Quantum Physics in Everyday Life00:04:34 - Understanding the Micro to Macro Connection00:08:11 - Weak Magnetic Fields and Cellular Response00:10:31 - Space Exploration and Magnetic Fields00:14:10 - Mars Colonization Challenges00:15:10 - Future Applications00:16:57 - Personal Backgrounds00:18:36 - From Quantum Sensors to Biology00:20:16 - The DeSci Connection00:27:07 - Real-World Applications Vision00:31:09 - Multiple Flavors of Quantum Biology00:35:45 - Music and Plant Growth00:43:19 - The Consciousness Question00:54:06 - Radical Open Science00:55:15 - How to Get Involved00:56:39 - Final Thoughts🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1______If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.toSpecial thanks to: ______Let's connect: Website: https://bit.ly/3d6nh2CTwitter: https://twitter.com/Molecule_daoDiscord: https://discord.gg/ZHGpJQzeTqMolecule - The future of medicine belongs to everyone
What if science wasn’t locked in labs or universities?
In episode 47 of the Molecule Podcast, we meet Juan Keymer, Assistant Professor, Shenzhen X-Institute who enlightens us on the existing academic pipeline and how it can be made more flexible with the advancement in AI, DeSci (Decentralized Science), Blockchain Innovation, Open Credentials and more.
• Reimagining the future of Science with DeSci.
• This is a deep, thoughtful, and radically hopeful conversation about the future of learning, research, and planetary collaboration.
• Indulge in a world of Science with Juan Keymer and Ella McCarthy-Page (SciComms Lead at Molecule) away from textbooks and traditional academic systems.
In this fascinating episode, we dive deep into reimagining the infrastructure of science away from elite institutions and toward decentralized, gamified systems that anyone can engage in.
Timestamps
00:00:00 – Introduction: A New Vision for Science
00:03:15 – The Problem with Academia & Closed Scientific Systems
00:10:47 – Open Degrees & Scope for Open Credentials
00:15:20 – The New Scientific Interface
00:20:34 – Biotic Games: How Living Systems Become Game Mechanics
00:28:45 – Open Hardware and Decentralized Labs
00:35:06 – Rewiring Academia: Parallel Programming & Self-Credentialing
00:37:00 – Metaverse & Blockchain-Powered Ecosystems
00:41:00 – Fun First, Research Second
00:43:00 – Final Reflections: The Power of Play in Scientific Discovery
🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1
______
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
______
Let's connect:
Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.gg/ZHGpJQzeTq
Molecule - The future of medicine belongs to everyone
Over $2.2 billion in NIH research grants are frozen. Labs are going dark. What happens now?
In Episode 46 of the Molecule Podcast, we speak with Aaron Weaver, Chief Commercial Officer at Molecule, about the ongoing NIH funding crisis, its global impact, and how decentralized science (DeSci) is becoming a critical alternative.
Aaron brings a unique vantage point from the intersection of venture capital, biotech, and public science funding. This episode unpacks:
• The real story behind the NIH funding freeze
• Why the budget cuts on indirect costs are threatening university research
• What happens when academia loses funding momentum
• How DeSci offers new models for sustainability and collaboration
• How to get involved — even if you’re not a researcherIf you care about the future of scientific discovery, this episode is essential.
Timestamps-
0:00 – Intro: The NIH funding crisis
1:30 – What’s actually frozen? Why $2.2B is stalled
2:50 – Meet Aaron Weaver: CCO of Molecule & DeSci advocate
5:00 – Why indirect costs are at the center of the issue
9:00 – How operational freezes threaten lab survival
11:30 – The fragility of foundational science
13:45 – NIH’s critical role in FDA-approved drugs
17:00 – Academic research vs. commercialization pipelines
20:15 – Who’s affected most? Young researchers & labs
23:00 – Global ripple effects & talent displacement
27:00 – Why traditional VC can’t fill the gap
30:10 – DeSci as a market structure for resilient funding
32:45 – Are universities ready for DeSci?
35:20 – Connecting scientists with global communities
37:10 – Science as public purpose and personal mission
40:00 – How you can get involved in the DeSci movement
🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1______If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.toSpecial thanks to: Aaron Weaver : https://x.com/RealAaronWeaverJillian Casalini : https://x.com/JillianCasalini______Let's connect: Website: https://bit.ly/3d6nh2CTwitter: https://twitter.com/Molecule_daoDiscord: https://discord.gg/ZHGpJQzeTqMolecule - The future of medicine belongs to everyone
What if your next spine surgery was coordinated by a DAO?
In Episode 48 of the Molecule Podcast, we’re joined by Vincent Challier, spine surgeon and co-founder of SpineDAO, and Virginie Lafage, medical strategist and Core Team member, to explore how decentralized science can transform a field as specialized and critical—as spinal health.
SpineDAO is building one of the first focused medical DAOs on the Bio Launchpad. In this episode, we cover:
• Why spinal health is overlooked in innovation
• The power of patient and clinician-led DAOs
• Challenges of onboarding medical professionals into DeSci
• Real-world use cases for DAOs in healthcare
• Why Solana? Technical decisions behind the DAO’s design
Whether you’re into biotech, DAOs, or the future of decentralized medicine, this conversation bridges science, surgery, and Web3 in a way you’ve never heard before.
⏱️ Timestamps
0:00 – Intro: Meet Vincent & Virginie from SpineDAO
2:10 – How they met and started the DAO
5:18 – From spine surgery to decentralization: Why this field?8:50 – Building a community around spine health
12:42 – Why spinal innovation is long overdue
17:20 – Challenges patients face in current medical systems
24:10 – How DAOs can unlock patient-centric research
29:45 – Engaging surgeons and clinicians in DeSci
36:30 – Building accessibility into Web3 onboarding
40:00 – Why SpineDAO chose Solana
44:23 – The Bio Launchpad auction and what’s next
49:04 – A message to their future community
52:10 – The real-world use case for SpineDAO
______
🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1
______
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
_________
Special thanks to:
Vincent Challier : https://x.com/challaire
Virginie Lafage : https://x.com/VirginieLafage
Ella McCarthy-Page :https://x.com/EMcCarthyPage
______
Let's connect:
Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.gg/ZHGpJQzeTq
Molecule - The future of medicine belongs to everyone
What if we could reinvent intellectual property for science? In this episode of Molecule’s DeSci Podcast, Kevin Noessler - Product Head at Molecule - joins us to talk about the next frontier of DeSci Science: Proof of Invention.
Kevin unpacks how Molecule is building infrastructure for decentralized IP creation, ownership, and attribution. This episode zooms in on how DeSci tools can validate and tokenize early-stage scientific ideas—before patents or papers.
We cover:
• Kevin’s background and his role in shaping Molecule’s product roadmap
• What “Proof of Invention” really means—and how it works onchain
• Rethinking IP and scientific reputation through cryptographic primitives
• UX challenges when designing for biotech DAOs
• The difference between building SaaS vs protocols in DeSci
• How open-source values translate into credible scientific infrastructure
Whether you’re an innovator, researcher, or builder—this episode is a roadmap for the future of intellectual property in science.⏱ Timestamps:
00:00 - Intro
01:10 - Kevin’s background & journey to Molecule
05:00 - What does a Product Head do in a decentralized org?09:20 - SaaS vs Protocol: Rethinking product building
13:00 - Contributors, not customers: the shift in stakeholder models
17:15 - UX challenges for onchain science tools
21:40 - What makes a product work in DeSci?
26:00 - Building with researchers in mind
30:30 - Kevin’s long-term vision for Molecule
35:00 - Advice for builders entering DeSci
39:20 - Outro
________
🔔 Subscribe to stay updated: https://www.youtube.com/@Molecule_dao/?sub_confirmation=1______
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
______
Special thanks to:
- Kevin Noessler: https://x.com/Noesslek
- Ella McCarthy-Page: https://x.com/EMcCarthyPage
______
Let's connect:
Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.gg/ZHGpJQzeTq
Molecule - The future of medicine belongs to everyone
What if the future of science and biotech was built on legal frameworks that empower communities, not corporations?
In Episode 44 of the Molecule Podcast, we sit down with Jesse Hudson — lawyer, anthropologist, and Chief Legal Architect at Molecule. Jesse is a pioneer in building legal infrastructure for decentralized science (DeSci), DAOs, and intellectual property (IP) tokenization.
This episode dives deep into:
- The failure of the current global IP system
- IP as cultural infrastructure
- IP tokenization and why it matters for DAOs
- Licensing, enforcement, and the problem of patent trolls
- How indigenous IP and cultural property are being reclaimed through blockchain
- New models for governance, dispute resolution, and community-owned IP
Jesse’s unique experience working with Amazonian tribes, biotech DAOs, and legal DAOs brings one of the most profound and ethical perspectives to the DeSci conversation.
Timestamps:0:00 – Intro: Why IP matters2:13 – Meet Jesse Hudson: Legal architect & anthropologist5:05 – From anthropology to biotech DAOs7:44 – IP in the digital age: Why it’s grown 70x11:02 – How IP impacts individuals: NIL rights & personal brands15:10 – IP basics: Trademark, copyright, patents20:05 – Patent trolls & the licensing problem27:01 – Is the IP system serving the public?30:10 – Tesla & IP strategy: When to share vs protect33:42 – DAOs as IP holders: SideDAO & decentralized licensing36:10 – IP tokens & collective governance38:18 – Indigenous cultural IP: Working with the Shipibo tribe44:20 – NFT royalties & licensing for indigenous art48:52 – IP ethics: Alternative models beyond Western frameworks53:22 – DAO-based dispute resolution & legal evolution59:50 – Closing thoughts: Cultural values driving IP systems🔗 Learn more at https://molecule.xyz
The psychedelic industry is booming, but a major battle is unfolding: Who will control the future of these powerful medicines? Will open science prevail, or will corporations dominate through patents? In this episode, we sit down with Graham Pechenik, a leading expert in psychedelic patent law, to unravel the complexities of intellectual property in the space.Graham Pechenik is the founder of Calyx Law, a law firm specializing in psychedelic and cannabis patents. With a background in neuroscience and law, he provides deep insights into the legal landscape shaping the future of psychedelic medicine.Topics Discussed:• The role of patents in psychedelic research• Controversies around corporate control and monopolization• How open-source models could challenge big pharma• What legal battles mean for researchers, startups, and patients• The future of psychedelic accessibilityTune in to get expert insights from one of the leading voices in psychedelic IP law.______If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.toSpecial thanks to: Ella McCarthy-Page - https://x.com/EMcCarthyPageGraham Pechenik - https://x.com/calyxlaw______Let's connect: Website: https://bit.ly/3d6nh2CTwitter: https://twitter.com/Molecule_daoDiscord: https://discord.gg/ZHGpJQzeTqMolecule - The future of medicine belongs to everyone
Biotech is at a crossroads—AI, intellectual property, and startups are reshaping the future. But who really controls the breakthroughs? In this episode, Sara Holland, an IP advisor, explores how patents impact biotech, the challenges startups face against big pharma, and whether AI will change everything.What You’ll Learn in This Episode:- The hidden barriers to biotech innovation- How AI is transforming drug discovery and synthetic biology- The role of patents in protecting—or stifling—progress- Why decentralized science (DeSci) could be the key to the future
______Special Thanks To:
Ella McCarthy-Page : https://x.com/EMcCarthyPage
Sara HollandChris Brynes
Mark Nichols
______
Let's connect: Website: https://bit.ly/3d6nh2C
Twitter: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
______
Molecule - The future of medicine belongs to everyone
Welcome to another episode of the DeSci Podcast. Today, we are discussing a critical issue that affects over 30 million people in the United States—Rare Diseases. Despite being more prevalent than cancer and HIV combined, rare diseases remain underfunded, overlooked by Big Pharma, and trapped in a broken system.Our Guest: This episode features Ethan Perlstein, founder of CureTopia, an initiative using Decentralized Science (DeSci) and blockchain to revolutionize rare disease research. Why does the current system fail millions of patients, and how can decentralized models change that?What You’ll Learn in This Episode:-The reality of rare diseases and why the term "rare" is misleading-How patients and parents are taking control of scientific research-Why Big Pharma does not prioritize rare diseases and the funding challenges involved-How DeSci and blockchain can disrupt traditional biotech and accelerate drug development-The vision behind CureTopia and how it is reshaping research for rare disease treatmentsResources Mentioned:CureTopia: https://curetopia.xyzDeSci Podcast: https://www.molecule.xyzFeel free to navigate through any of the topics discussed in the podcast using the timestamps below.___⭐ Timestamps:0:00 - Introduction: The Rare Disease Crisis2:14 - Why Rare Diseases Are More Common Than People Think5:13 - Challenges in Rare Disease Advocacy9:25 - How Parents Become Scientific Experts in Their Child’s Disease13:50 - Why Big Pharma Ignores Rare Diseases17:16 - The Role of Decentralized Science (DeSci) in Drug Development22:41 - The Funding Challenges in Rare Disease Research27:34 - How Blockchain and Smart Contracts Can Help Rare Disease Research33:04 - The Power of Community in Rare Disease Advocacy38:26 - What Is CureTopia and How Does It Work?43:57 - The Future of Rare Disease Research and Biotech Innovation49:14 - Ethan Perlstein’s Vision for CureTopia54:10 - Closing Thoughts and Where to Learn More______If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.toSpecial thanks to:Jillian Casalini: https://x.com/JillianCasaliniEthan Perlstein: https://x.com/eperlste____Let's connect: Website: https://bit.ly/3d6nh2CX: https://twitter.com/Molecule_daoDiscord: https://discord.com/invite/moleculedaoMolecule - The future of medicine belongs to everyone!
Welcome to another episode of the DeSci Podcast! Today, we’re excited to host Joshua Bate, Founder of DeSciWorld. DeSciWorld is a community-driven initiative dedicated to facilitating the onboarding of individuals into the Decentralized Science (DeSci) space.
It provides users with the tools to view, engage with, and understand everything happening in the world of decentralized science.
In this episode, Joshua shares the vision behind DeSciWorld and its role as a global hub for the decentralized science community. We touch on Joshua's frank thoughts on the DeSci movement and how open discussion and unadultered knowledge transfer, alongside powerful incentives, are necessary to grow the space.
We also discuss the “Proof of Knowledge protocol”, DeSciWorld's upcoming technical product where users can upload data and receive incentives whenever their contributions are utilized. Joshua addresses concerns about spam and low-quality dataset submissions, as well as potential technical approaches to ensure that the data used to train AI remains high-quality and reliable.
DeSci World: https://desci.world/
SynapseDAO: https://synapse-dao.webflow.io/
Feel free to navigate through any of the topics discussed in the podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
1:28 Overview of DeSci World
04:24 About “Proof of Knowledge” protocol
7:07 Ensuring high-quality datasets
14:04 Common misconceptions about DeSci
16:28 How incentives can drive DeSci adoption in Academia
20:10 Underappreciated aspects of Decentralized Science
22:10 Recommendations for getting started in DeSci
24:23 Competition vs. collaboration in the Web3 space
25:48 Scope of biotech
30:59 The future of of Decentralized Science
33:55 Outro
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea: https://twitter.com/lealeata
Joshua: https://twitter.com/jb87ua
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
In this episode, we're diving deep into Molecule's Catalyst, an incentive-driven funding system for basic research. We begin by exploring the significant challenges posed by traditional funding models. We then touch on the "Valley of Death"—a critical juncture where many groundbreaking ideas fail often due to a lack of financial support.
We discuss why early-stage research often struggles to gain traction and the barriers that prevent innovative ideas from reaching their full potential.
Catalyst is at the forefront of addressing these issues with its decentralized approach. By realigning incentives and democratizing access to research funding, Catalyst fosters collaboration and makes science more inclusive and inviting.
We also explore the role of IP tokens (IPTs) in decentralized science and how they democratize access to and control over scientific advancements. Additionally, we explain Catalyst’s bonding curve, which features dynamic pricing that rewards early backers with lower token prices and ensures fair pricing as more tokens are minted. This system not only incentivizes early support but also maintains a transparent and equitable funding environment.
Tune in to discover the potential of decentralized funding in science and how you can get involved. Whether you're a researcher, an investor, or simply curious about the future of science, this episode is packed with insights you won't want to miss.
___
⭐ Timestamps:
0:00 Intro
18:04 Challenges of traditional funding models
19:47 The valley of death; how it impacts research
24:30 Difficulty in getting involved in early-stage ideas
31:20 Using IP as a tool to realign incentives
35:01 Why IP is the ideal use case for bringing ideas on-chain
42:05 Decentralized funding in science
48:44 Introduction to Catalyst
55:26 How Catalyst works
59:36 Catalyst bonding curve explained
1:03:22 The negotiation period in Catalyst fundraising
1:09:22 Final remarks
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Jillian: https://twitter.com/JillianCasalini
Benji: https://twitter.com/benjileibo
Kevin: https://www.linkedin.com/in/kevin-noessler
Learn more about Catalyst here: https://catalyst.molecule.xyz/
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
In this episode, we have the pleasure of hosting Alok Tayi, the co-founder of Vibe Bio.Vibe Bio is a life science company dedicated to investing in biotech firms, with a special focus on rare and overlooked diseases.
In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases with unmet needs, leveraging AI to find medicines with the highest chances of providing cures.
We discuss the complexities of drug development, the advantages of DAOs as an organizational structure and common misconceptions within the Biopharma industry. Alok also shares his insights on the transformative role of AI in drug discovery, discussing its utilization, the methods used for training AI models, the issue of AI bias, and the current limitations and challenges faced in leveraging AI to advance drug development.
Feel free to navigate through any of the topics discussed in the podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
01:51 What led you to create Vibe
02:52 Diseases Vibe Focuses On
04:37 Complexities in Drug Development
7:49 Advantages of DAOs
12:00 Misconceptions in Academia & the Private Sector
16:53 Areas you’re willing to explore with more funding.
23:59 Utilizing AI tools in Drug Discovery
28:50 Bias in AI
32:54 AI Training Methods
36:58 Limits of AI in Drug Discovery
39:56 Implicit Knowledge in Drug Development
49:30 Outro
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea: https://twitter.com/lealeata
Alok: https://twitter.com/aloktayi
Learn more about Vibe Bio here: https://vibebio.com/
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
Welcome to another episode of the DeSci Podcast. Today, we're joined by Justin, Head of Growth at Hippocrat, a collaborative healthcare data protocol that aims to transform healthcare by empowering individuals to take control of their health data through blockchain and zero-knowledge proof technologies.
In this episode, we discuss the importance of data sovereignty, exploring how Hippocrat's innovative approach ensures secure and private data management, enabling safe and transparent data sharing with healthcare providers.
Justin emphasizes the need for decentralized data provision in healthcare, stressing that shifting from centralized to decentralized data management addresses the longstanding issue of individuals lack of control over their health data, which in turn advances personalized healthcare and research.
We also explore Hippocrat's collaboration with Research HUB, aimed at identifying potential populations and regions where Hippocrat's telemedicine application, ‘Hippodoc’, could be effectively deployed to bridge healthcare accessibility gaps.
Feel free to navigate through any of the topics discussed in the podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
1:28 About Hippocrat
2:37 Why data sovereignty is important
7:55 The inspiration behind Hippocrat
11:48 Moving from Web 2 to Web 3 healthcare
13:39 How Hippocrat improves Data security
22:27 $HPO token utility and upcoming airdrop
26:58 Collaboration with Research HUB
38:25 How the Hippodoc app works
41:27 Hippocrat role in the DeSci space
45:30 Hippocrat in 10 years
49:18 How to get involved
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Ella McCarthy-Page: https://twitter.com/EMcCarthyPage
Justin Kim: (email: justin@hippocrat.io / telegram: just_in_1)
Special Airdrop for DeSci Podcast listeners: https://gleam.io/cLiQO/100-hippocrat-x-desci-podcast-giveaway
Learn more about Hippocrat here: https://link3.to/hippocrat
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
In this episode we're joined by Dr. Sönke Bartling, Founder of Blockchain for Science, an initiative that aims to open up science and knowledge creation through web3.
In this episode, we explore Decentralized Science (DeSci) and its potential to revolutionize research, publishing, and innovation! We dive deep into how blockchain technology can transform scholarly publishing by making it more transparent, efficient, and trustworthy.
We also discuss how DeSci can address funding inequality by supporting both high-profile topics, such as longevity research, and smaller yet vital fields. This, in turn, enables DeSci to promote diversity in research and unlock breakthroughs in overlooked areas.
We further discuss how DeSci can revolutionize the peer review process and explore the future of patents in a DeSci landscape, where research is incentivized without hindering collaboration, and how this can lead to more innovative scientific discoveries.
Feel free to navigate through the various topics covered in the Podcast using the timestamps provided below.
___
⭐ Timestamps:
0:00 Intro
1:46 Blockchains in the Future of Science and Research
4:25 Blockchain Adoption in Publishing
5:45 Underappreciated Aspects of DeSci
12:06 Radical Guidelines for Web3
17:19 Transitioning more Scientists to DeSci
25:26 What limits Institutional Change with Technology
30:22 Incentivising Foolproof DeSci
33:12 Plausibility and Reproducibility in Peer Review
36:16 Standards for Peer Review
39:14 DeSci for Publishing
40:25 The Private Sector and Academia
43:59 Non-monopolizing Patents with Web3
46:36 Further Questions
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea Degen: https://twitter.com/lealeata
Dr. Sönke Bartling: https://twitter.com/soenkeba
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
In this episode, we discuss the problem of declining R&D efficiency with Dr. Jack Scannell, a scientist and entrepreneur who is well known for coining the term “Eroom’s law,” which highlights the decline in pharmaceutical research and development (R&D) productivity over several decades.
In this episode, Jack sheds light on the root causes of this decline, beginning with a critique of the poor quality of diagnosis surrounding the R&D productivity problem.
He also talks about the challenges in accurately measuring progress in drug research, highlighting the "measurement problem" in the drug industry. Jack suggests adopting a model akin to the "Stern Review” to improve the diagnosis of these challenges.
Jack also addresses topics such as the shift in the frequency of serendipitous drug discoveries, the Eroom’s law article, the entanglement of science, money and drug development and many more.
Feel free to navigate through any of the topics discussed in the Podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
01:40 Poor quality of diagnosis of the R&D productivity problem
04:01 The measurement problem
09:21 Chesterton’s fence of R&D
14:38 Science, Drug development, Money.
20:46 The role of Serendipity in drug discovery
26:34 Economics in the drug industry.
34:43 Implicit knowledge within Biotech
41:43 Eroom's Law paper
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea Degen: https://twitter.com/lealeata
Jack Scannell: https://twitter.com/JackScannell13
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
Welcome to another episode of the DeSci Podcast. Today, we were joined by Jeffrey Koury, Director & Business Development Lead at ResearchHub, and Jonathan Heppner, Marketing & Social Media Lead.
ResearchHub is a platform designed to accelerate the pace of scientific research by providing a modern mobile and web application where people can collaborate on scientific research more efficiently. It aims to make scientific research accessible, collaborative, and prioritized for everyone.
In this episode, we delved into the shortcomings of the current scientific research model and the need to make science open to everyone.
Our dialogue centered on advocating for a shift from the traditional model towards a more inclusive and transparent system. Central to this shift is the necessity of building better incentive structures, which would drive collaboration among scientists and facilitate accelerated progress in scientific research.
Feel free to navigate through any of the topics discussed in the Podcast using the timestamps below.
___
⭐ Timestamps:
0:00 Intro
1:30 What is Research Hub?
03:05 Onboarding process.
05:40 What drove your interest in building Research Hub?
12:16 Past efforts in promoting open science
18:32 The role of Research Hub in scientific literature
26:19 How Research Hub differs from traditional journals
35:14 Public versus Anonymous Peer Review
39:20 Most contentious topics within your field
48:50 Ensuring high quality science
52:35 Why books are important
59:13 How to get involved
59:47 How Research Hub has evolved over the years
1:05:13 Outro
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea Degen: https://twitter.com/lealeata
Jeffrey Koury: https://twitter.com/jeffyfish9
Jonathan Heppner: https://twitter.com/EnactJohnny
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
Today we are delighted to host Seemay Chow, Co-founder and CEO of Arcadia Science, a for-profit research institute with a specific focus on novel model organisms that haven't been traditionally studied in the lab and translating discoveries into commercial ventures.
In this episode, we discuss Arcadia’s mission, structure and approach, emphasizing the importance of providing scientists with the context needed to understand the practical applications of their research. Seemay explains how this approach fosters a different kind of creativity among researchers, thus increasing the likelihood of research success.
We also explore the limitations researchers face in the traditional setting while further highlighting the strengths and weaknesses of Academia and industry. Other topics we touched on include notions of diversity in science, strategies for spotting the best talents and ideas to fund, and many more.
Feel free to navigate through the various topics covered in the Podcast using the timestamps provided below.
___
⭐ Timestamps:
0:00 Intro.
0:49 Effects of running a for-profit venture on Arcadia’s structure.
3:05 What is Arcadia?
7:35 Researchers limitations in Academia.
11:45 Academia vs the private sector.
16:21 Insights gained from building Arcadia.
27:54 Arcadia structure.
30:38 Diversity in science.
35:24 Strategies for discovering the best talents.
43:28 Contextualizing science.
49:50 Outro.
____
If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below.
If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to
Special thanks to
Lea Degen: https://twitter.com/lealeata
Seemay Chou: https://twitter.com/seemaychou
____
Let's connect:
Website: https://bit.ly/3d6nh2C
X: https://twitter.com/Molecule_dao
Discord: https://discord.com/invite/moleculedao
